NCT02864888View on ClinicalTrials.gov

Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2027

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Brain Stem Glioma
Interventions
RADIATION

Radiation

Children with a diffuse, intrinsic brain stem glioma will receive radiation.

DRUG

Atengenal

Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation

DRUG

Astugenal

Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER